Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:25:53 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Z:AZN - ASTRAZENECA PLC - https://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Z0.2191.00·197.000.1193.03+5.9053.23,117.6573,55330,920190.46  193.97  188.49192.79  61.2419:55:30Feb 0315 min RT 2¢

Recent Trades - Last 10 of 30920
Time ETExPriceChangeVolume
19:55:30Z194.407.2410
19:17:37Z193.91536.75531
18:49:12Z193.005.84162
18:24:06Z195.007.841
18:16:50Z195.007.8440
18:06:57Z194.227.069
18:06:57Z194.227.0625
18:03:46Z194.507.345
17:44:37Z195.007.841
17:35:39Z191.003.841

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-03 07:00U:AZNNews ReleaseDATROWAY(TM) (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
2026-02-02 07:00U:AZNNews ReleaseAstraZeneca begins trading on the New York Stock Exchange
2026-01-08 07:00U:AZNNews ReleaseRick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
2025-12-22 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
2025-12-15 16:29U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
2025-12-04 07:00U:AZNNews ReleaseAstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
2025-12-02 09:18U:AZNNews ReleaseBaxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
2025-11-26 07:00U:AZNNews ReleaseIMFINZI(TM) approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
2025-11-21 14:05U:AZNNews ReleaseAstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
2025-11-09 16:33U:AZNNews ReleaseBaxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
2025-11-07 09:00U:AZNNews ReleaseStatistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
2025-11-06 07:00U:AZNNews ReleaseAstraZeneca's 9M and Q3 2025 Financial Results
2025-11-06 07:00U:AZNNews ReleaseAxsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
2025-10-19 07:00U:AZNNews ReleaseDATROWAY(TM) (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
2025-10-18 10:35U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
2025-10-18 10:30U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
2025-10-17 16:17U:AZNNews ReleaseTEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
2025-10-17 08:10U:AZNNews ReleaseIMFINZI(TM) (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
2025-10-17 08:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
2025-10-15 10:00U:AZNNews ReleaseAstraZeneca unveils expanded manufacturing facility in Texas